成人成長ホルモン欠乏症（AGHD）患者に対するソグロヤ®の長期安全性情報追跡調査

基本情報

NCT ID

NCT05718570

ステータス

招待制

試験のフェーズ

-

試験タイプ

観察

目標被験者数

400

治験依頼者名

Novo Nordisk A/S

概要

In this study, the general long-term safety and effectiveness of Sogroya (somapacitan) in adults with growth hormone deficiency (AGHD) being treated per normal clinical practice is looked into. In the study, information on side effects and how well Sogroya (somapacitan) works during long term treatment in people with Adult Growth Hormone Deficiency (AGHD) will be collected and analysed. Participants will be treated with Sogroya (somapacitan) as prescribed by the study doctor, in accordance with normal clinical practice. The study will last for 5-10 years, depending on when the participant join the study. The participant will be asked to complete two short questionnaires during every visit to the clinic. The questionnaires will collect information on the participant's well-being, work ability and ability to perform daily activities.

対象疾患

介入

依頼者（Sponsor）

実施施設 (6)